Detroit, MI
--News Direct--
Evofem Biosciences, Inc., EVFM is a biopharmaceutical company developing & commercializing products to address needs in women's sexual & reproductive health. The Company's 1st FDA-approved product, Phexxi® (lactic acid, citric acid & potassium bitartrate), is a hormone-free prescription contraceptive vaginal gel. The Company may report top-line data in fall 2022 from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for 2 potential new indications – prevention of chlamydia & of gonorrhea in women. Visit phexxi.com & evofem.com.
Contact Details
Benzinga
+1 877-440-9464
Company Website
View original content to download multimedia: https://newsdirect.com/news/evofem-biosciences-inc-ceo-saundra-pelletier-discusses-why-evfm-is-a-company-to-watch-625266353
2022 News Direct Corp.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.